{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:18Z","timestamp":1793895978680,"version":"4.8.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016599","name":"Purdue University Purdue Institute for Drug Discovery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM150507"],"award-info":[{"award-number":["R35GM150507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM146786"],"award-info":[{"award-number":["R35GM146786"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM142743"],"award-info":[{"award-number":["R35GM142743"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jconrel.2026.115053","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:12:36Z","timestamp":1779750756000},"page":"115053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination"],"prefix":"10.1016","volume":"396","author":[{"given":"Dahee","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziye","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Abi Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal T.","family":"Ramseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Oe","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve Seung-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115053_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0010","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2016.05.073","article-title":"Personalized cancer vaccines: targeting the cancer mutanome","volume":"35","author":"Zhang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2026.115053_bb0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0035","article-title":"Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment","volume":"45","author":"Me","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115053_bb0040","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115053_bb0045","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115053_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2026.115053_bb0060","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","article-title":"PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematologic malignancies in the adjuvant setting","volume":"15","author":"Saxena","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2026.115053_bb0065","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3390\/vaccines12080950","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2026.115053_bb0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1670","article-title":"Dendritic-cell trafficking to lymph nodes through lymphatic vessels","volume":"5","author":"Randolph","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115053_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/vaccines8010128","article-title":"Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant-antigen codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2026.115053_bb0085","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-17-0607","article-title":"Enhancement of peptide vaccine immunogenicity by increasing lymphatic drainage and boosting serum stability","volume":"6","author":"Moynihan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115053_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115053_bb0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.actbio.2024.12.039","article-title":"Impact of nanoparticle properties on immune cell interactions in the lymph node","volume":"193","author":"Farooq","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.115053_bb0100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0110","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115053_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0120","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.biomaterials.2012.12.031","article-title":"A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy","volume":"34","author":"Yuba","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115053_bb0125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115053_bb0130","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0135","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115053_bb0140","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20032220","article-title":"In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination","volume":"199","author":"Bonifaz","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0145","doi-asserted-by":"crossref","first-page":"232ra51","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87102","article-title":"Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition","volume":"1","author":"Tullett","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.115053_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000691","article-title":"Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate na\u00efve and memory NY-ESO-1-specific CD8+ T cells","volume":"8","author":"Masterman","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115053_bb0160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cancers11030418","article-title":"Use of dendritic cell receptors as targets for enhancing anti-cancer immune responses","volume":"11","author":"Hossain","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115053_bb0165","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0175","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0180","first-page":"61","article-title":"Anti-CD40 agonist antibodies: preclinical and clinical experience, update","volume":"2","author":"Khalil","year":"2007","journal-title":"Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0185","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1172\/JCI125740","article-title":"Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes","volume":"129","author":"K\u00e4h\u00e4ri","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115053_bb0190","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4939-2272-7_12","article-title":"Site-specific biotinylation of purified proteins using BirA","volume":"1266","author":"Fairhead","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0195","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jacsau.2c00617","article-title":"Enzymatic bioconjugation: a perspective from the pharmaceutical industry","volume":"3","author":"Debon","year":"2023","journal-title":"JACS Au"},{"key":"10.1016\/j.jconrel.2026.115053_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115053_bb0205","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115053_bb0210","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1007\/s00253-018-9377-7","article-title":"Functional expression of monomeric streptavidin and fusion proteins in Escherichia coli: applications in flow cytometry and ELISA","volume":"102","author":"Kroetsch","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0215","first-page":"69","article-title":"The lymph system in mice","volume":"12","author":"Kawashima","year":"1964","journal-title":"Jpn. J. Vet. Res."},{"key":"10.1016\/j.jconrel.2026.115053_bb0220","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1021\/bi2010366","article-title":"Engineered streptavidin monomer and dimer with improved stability and function","volume":"50","author":"Lim","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2026.115053_bb0225","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115053_bb0230","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.jconrel.2026.115053_bb0235","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jim.2007.11.012","article-title":"Lymph node mapping in the mouse","volume":"332","author":"Harrell","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2026.115053_bb0240","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jim.2007.08.004","article-title":"Hock immunization: a humane alternative to mouse footpad injections","volume":"328","author":"Kamala","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2026.115053_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019198","article-title":"Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103\u2212 and XCR1+CD103+ dendritic cells","volume":"4","author":"Wylie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115053_bb0250","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.immuni.2010.12.011","article-title":"CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens","volume":"34","author":"Asano","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115053_bb0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/vaccines13030330","article-title":"Exploring CD169+ macrophages as key targets for vaccination and therapeutic interventions","volume":"13","author":"Bouma","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2026.115053_bb0260","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0b013e318165f5d2","article-title":"Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale","volume":"31","author":"Kaka","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2026.115053_bb0265","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.4049\/jimmunol.181.12.8576","article-title":"IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17","volume":"181","author":"Henry","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0270","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/2326-6066.CIR-13-0157","article-title":"Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines","volume":"2","author":"Weir","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115053_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101463","article-title":"Streptavidin promotes DNA binding and activation of cGAS to enhance innate immunity","volume":"23","author":"Zhang","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2026.115053_bb0280","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2003-12-4291","article-title":"Tracking CD40 signaling during germinal center development","volume":"104","author":"Basso","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.115053_bb0285","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1126\/science.1071914","article-title":"The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation","volume":"298","author":"Hoffmann","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2026.115053_bb0290","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41467-022-29718-2","article-title":"T cell receptor and IL-2 signaling strength control memory CD8+ T cell functional fitness via chromatin remodeling","volume":"13","author":"Chin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115053_bb0295","article-title":"Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer","volume":"9","author":"Hos","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2026.115053_bb0300","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0305","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115053_bb0310","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-14-0019-T","article-title":"Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes","volume":"2","author":"Jeanbart","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2026.115053_bb0315","first-page":"257","article-title":"Monoclonal antitumor antibodies in the lymphatics","volume":"68","author":"Weinstein","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.jconrel.2026.115053_bb0320","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/JLB.5RI0220-603RR","article-title":"Harnessing neoantigen specific CD4 T cells for cancer immunotherapy","volume":"107","author":"Brightman","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0325","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.4049\/jimmunol.178.7.4169","article-title":"Delivery of antigen to CD40 induces protective immune responses against tumors","volume":"178","author":"Schjetne","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0330","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1084\/jem.20121251","article-title":"Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation","volume":"210","author":"Cohn","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0335","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(96)00173-1","article-title":"Preferential labeling of alpha-amino N-terminal groups in peptides by biotin: application to the detection of specific anti-peptide antibodies by enzyme immunoassays","volume":"199","author":"S\u00e9lo","year":"1996","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2026.115053_bb0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bioeng.2007.02.003","article-title":"Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum","volume":"24","author":"Barat","year":"2007","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.jconrel.2026.115053_bb0345","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115053_bb0350","first-page":"1","article-title":"Boosting therapeutic potency of antibodies by taming fc domain functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115053_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111934","article-title":"Correlative multiscale 3D imaging of mouse primary and metastatic tumors by sequential light sheet and confocal fluorescence microscopy","volume":"28","author":"Zheng","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2026.115053_bb0360","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1038\/s41467-025-58779-2","article-title":"Unveiling cellular communications through rapid pan-membrane-protein labeling","volume":"16","author":"Gunasekara","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115053_bb0365","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0370","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"R\u00fcter","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0375","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2567.2003.01634.x","article-title":"A potent adjuvant effect of CD40 antibody attached to antigen","volume":"109","author":"Barr","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2026.115053_bb0380","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.4049\/jimmunol.1102390","article-title":"Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo","volume":"189","author":"Flamar","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786144","article-title":"Anti-CD40 antibody fused to CD40 ligand is a superagonist platform for adjuvant intrinsic DC-targeting vaccines","volume":"12","author":"Ceglia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115053_bb0390","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1038\/s41467-024-53839-5","article-title":"A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T cell proliferation and anti-tumor immunity in mice","volume":"15","author":"Mebrahtu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115053_bb0395","article-title":"An adaptable antibody-based platform for flexible synthetic peptide delivery built on agonistic CD40 antibodies","volume":"5","author":"Eltahir","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.115053_bb0400","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:48:04Z","timestamp":1793893684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"alternative-id":["S0168365926004566"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115053","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.30.663779","asserted-by":"object"}]},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115053"}}